ABSTRACT
The purpose of this current opinion article is to illustrate a novel approach to the treatment of acute decompensated heart failure (ADHF) in coronavirus disease 2019 (COVID-19) patients. The approach described herein relies on a reformulation of intravenous nitroglycerin in 5% glutathione, itself novel, and is felt to have the potential to not only improve the rate of resolution of ADHF, but also reduce the risk of complications of heart failure seen in patients with COVID-19.
Subject(s)
COVID-19/complications , Heart Failure/diagnosis , Heart Failure/etiology , Nitroglycerin/therapeutic use , Vasodilator Agents/therapeutic use , Administration, Intravenous , Drug Compounding , Glutathione/chemistry , Humans , Infusions, Intravenous , Nitroglycerin/chemistry , Vasodilator Agents/chemistryABSTRACT
ABSTRACT: The involvement of the vascular endothelium in the complications of coronavirus disease 2019 is now recognized. Chief among these are pulmonary endotheliitis, cytokine storm, endotoxic shock, and cardiovascular collapse. This Perspectives article is focused on therapeutical strategies to reduce the risk of these complications by targeting the vascular endothelium as a part of the overall treatment of coronavirus disease 2019.